(IN BRIEF) Sanofi has announced the discontinuation of the global clinical development program for tusamitamab ravtansine, following an interim analysis…
(IN BRIEF) The Phase 3 IMROZ trial, assessing the use of Sarclisa® (isatuximab) in combination with standard-of-care bortezomib, lenalidomide, and…